,,ii #aahth ,,congress #b;d ,session ,s4 #difd ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,august #a1 #bjbd,mr4 ,sanders 7for himself1 ,ms4 ,duckworth1 ,mr4 ,kaine1 ,mr4 ,markey1 ,ms4 ,smith1 and ,mr4 ,welch7 introduced the following bill2 which was read twice and referred to the ,committee on ,health1 ,education1 ,labor1 and ,pensions ,a ,,bill ,to provide for a comprehensive ,federal response to ,long ,,covid1 including research1 education1 and support for affected individuals1 to direct the ,national ,institutes of ,health to establish a ,long ,,covid research program1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,long ,,covid ,research ,moonshot ,act4 ,i ,long ,,covid ,biomedical ,research #aja4 ,establishment of ,long ,,covid research program ,title ,,iv of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bha et seq47 is amended by adding at the end the following3 ,k ,long ,,covid programs #dii;,b4 ,establishment of ,long ,,covid research program 7a7 ,in general ,there is established within the ,office of the ,director of the ,national ,institutes of ,health a research program1 to be known as the ,long ,,covid ,research ,program 7referred to in this part as the ,program71 for purposes of expediting research to identify new ways to prevent1 detect1 manage1 and treat symptoms associated with ,long ,,covid4 7b7 ,director 7#a7 ,appointment 7,a7 ,in general ,the ,program shall be headed by a ,director1 appointed by the ,secretary1 in consultation with the ,director of ,,nih1 who has-- 7i7 experience managing clinical or research programs focused on pathogenic mechanisms and biological pathways related to ,long ,,covid2 and 7ii7 demonstrated commitment to addressing ,long ,,covid and other infection-associated chronic conditions1 such as myalgic encephalomyelitis_/chronic fatigue syndrome1 postural orthostatic tachycardia syndrome1 and post-treatment ,lyme disease syndrome_/persistent ,lyme disease4 7,b7 ,consultation ,in appointing the ,director under subparagraph 7,a71 the ,secretary shall consult with independent1 patient-led organizations or advocacy groups representing ,long ,,covid patients and their families4 7#b7 ,responsibilities ,the ,director of the ,program shall-- 7,a7 act as the primary ,federal official with responsibility for coordinating all ,long ,,covid research conducted or supported by the ,national ,institutes of ,health2 7,b7 represent the ,national ,institutes of ,health ,long ,,covid ,research ,program at all relevant ,executive branch task force meetings and committees2 and 7,c7 maintain communication with all relevant ,federal departments and agencies to ensure the timely transmission of information concerning advances in ,long ,,covid research and the clinical treatment of ,long ,,covid and other infection-associated chronic conditions between such departments and agencies1 and for dissemination to affected communities and health care providers4 7c7 ,activities ,the ,program shall-- 7#a7 investigate the etiology1 pathophysiology1 risk factors1 and pathology of ,long ,,covid in adults and children2 7#b7 explore the best ways to prevent1 detect1 monitor1 manage1 and treat ,long ,,covid in adults and children2 7#c7 contribute knowledge to the understanding1 prevention1 mitigation1 management1 and treatment of ,long ,,covid2 7#d7 develop and facilitate programs on ,long ,,covid1 within the ,national ,institutes of ,health and in other settings2 7#e7 conduct comparative research to understand the similarities and differences between ,long ,,covid and other infection-associated chronic conditions with similar phenotypes1 such as myalgic encephalomyelitis_/chronic fatigue syndrome1 postural orthostatic tachycardia syndrome1 and post-treatment ,lyme disease syndrome_/persistent ,lyme disease1 and how activities funded by the ,program could improve understanding of such other conditions2 and 7#f7 conduct comparative research to understand the similarities and differences between ,long ,,covid and severe1 long-term effects from ,,covid-#ai vaccinations4 7d7 ,duties 7#a7 ,interagency coordination of long covid activities ,the ,director of the ,program shall coordinate with the national research institutes and national centers1 as appropriate1 on ,long ,,covid research4 ,in carrying out this paragraph1 the ,director of the ,program shall evaluate the ,long ,,covid activities of each such institute or center and shall provide for the periodic reevaluation of such activities4 7#b7 ,consultation ,the ,director of the ,program shall carry out all duties1 including the development of the research plan under section #dii;,b-#a in consultation with the heads of the national research institutes and national centers1 with the advisory councils of such institutes and centers1 and with the ,long ,,covid ,research ,program ,advisory ,board established under section #dii;,b-#d4 7e7 ,non-,duplication of effort ,the ,director shall ensure that activities carried out under this section do not unnecessarily duplicate the efforts of other ,federal departments or agencies4 #dii;,b-#a4 ,long ,,covid ,research ,plan 7a7 ,in general ,not later than #a year after the date of enactment of the ,long ,,covid ,research ,moonshot ,act1 the ,director of the ,program established under section #dii;,b shall develop and make public a comprehensive research plan for the conduct and support of all ,long ,,covid research activities of the national research institutes and national centers4 ,the ,director of the ,program shall update such plan annually4 7b7 ,contents ,the research plan developed under subsection 7a7 shall-- 7#a7 identify current ,long ,,covid research conducted or supported by the national research institutes and national centers1 opportunities and needs for additional research1 including among patients who face the highest disease burden and pediatric patients1 and priorities for such research2 7#b7 evaluate the progress of ,long ,,covid research against strategic priorities1 goals1 and objectives1 identified in previous versions of the research plan2 7#c7 make recommendations for the coordination of such research conducted or supported by the ,national ,institutes of ,health and other agencies of the ,federal ,government2 and 7#d7 include goals and objectives of the ,program for conducting1 supporting1 and coordinating ,long ,,covid research4 7c7 ,requirements ,in developing the research plan under subsection 7a71 the ,director of the ,program shall-- 7#a7 ensure that the plan establishes priorities among ,long ,,covid research that the ,program is authorized to carry out2 7#b7 ensure that the plan establishes objectives regarding such research and describes the means for achieving the objectives2 7#c7 ensure that all amounts appropriated for such research under section #dii;,b-#f are expended in accordance with the plan2 7#d7 review the plan not less frequently than annually1 and revise the plan as appropriate to prioritize funding and research relative to scientific urgency2 7#e7 ensure that the plan serves as a broad1 binding statement of policies regarding ,long ,,covid research of the ,national ,institutes of ,health1 but does not affect the responsibility of any of the national research institutes or centers with respect to the programs or projects of such institutes and centers2 and 7#f7 annually prepare and submit to the ,director of ,,nih for review and transmittal by the ,director of ,,nih to the ,president and to ,congress a budget estimate for carrying out the plan for the upcoming fiscal year4 7d7 ,consultation ,in developing1 implementing1 reviewing1 and prioritizing elements of the research plan under this section1 the ,director of the ,program shall consult1 as appropriate with-- 7#a7 representatives of other ,federal agencies involved in ,long ,,covid research1 including the ,centers for ,disease ,control and ,prevention1 the ,agency for ,healthcare ,research and ,quality1 and the ,administration for ,community ,living2 7#b7 the ,long ,,covid ,research ,advisory ,board established under section #dii;,b-#d2 7#c7 the ,office of ,long ,,covid ,research and ,practice of the ,department of ,health and ,human ,services2 7#d7 leading scientific experts on ,long ,,covid2 and 7#e7 independent1 patient-led organizations or advocacy groups representing patients with ,long ,,covid and other infection-associated chronic conditions with similar phenotypes1 and the families of such patients4 7e7 ,report ,the ,director of the ,program shall submit the research plan developed under subsection 7a71 and updates to such plan1 to-- 7#a7 the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate2 7#b7 the ,committee on ,energy and ,commerce of the ,house of ,representatives2 7#c7 the ,secretary2 7#d7 the ,office of ,long ,,covid ,research and ,practice of the ,department of ,health and ,human ,services2 and 7#e7 the ,director of ,,nih1 who shall post the plan1 and updates to the plan1 on the website of the ,national ,institutes of ,health4 #dii;,b-#b4 ,expedited ,long ,,covid research 7a7 ,in general ,the ,director of ,,nih shall establish a process to expedite the award of grants1 contracts1 and cooperative agreements for research projects conducted or supported by the ,national ,institutes of ,health and relating to ,long ,,covid4 7b7 ,requirements for making external funding available ,with respect to programs of grants1 contracts1 and cooperative agreements described in subsection 7a71 the ,director of ,,nih shall-- 7#a7 make publicly available the deadlines for submitting applications for such programs1 and ensure that such deadlines provide applicants with sufficient time from the date of the announcement for such grant1 contract1 and cooperative agreement to submit an application2 7#b7 ensure that applicants receive a final decision on their applications within #abj days of submission2 and 7#c7 with respect to applications that are denied1 provide a written explanation to the applicant on the reasons for the denial4 7c7 ,evaluation of ,grant ,applications ,in making a determination to award a grant1 contract1 and cooperative agreement for research projects described in subsection 7a71 the ,director of ,,nih shall-- 7#a7 give priority to research that-- 7,a7 tests the outcomes of existing drug and device interventions in patients with ,long ,,covid2 7,b7 focuses on identifying interventions for pediatric patients with ,long ,,covid2 7,c7 aids in the development of new interventions that have evidence to suggest effectiveness in treating or curing ,long ,,covid2 or 7,d7 includes institutions that represent1 or have a successful track record of providing equitable care or services to1 historically underserved communities2 7#b7 consider research that has the ability to begin interventions in a timely manner2 7#c7 consider research that uses decentralized trials or remote monitoring techniques for data collection2 and 7#d7 consider research that includes patients with other infection-associated chronic conditions with similar phenotypes1 such as myalgic encephalomyelitis_/chronic fatigue syndrome1 postural orthostatic tachycardia syndrome1 and post-treatment ,lyme disease syndrome_/persistent ,lyme disease4 7d7 ,reasonable pricing ,in awarding contracts1 grants1 and cooperative agreements for research projects described in subsection 7a7 that relates to the development of a drug or device for the potential treatment or management of ,long ,,covid1 or identifying a new indication or use specific to the treatment or management of ,long ,,covid in a drug or device that is already approved or cleared by the ,food and ,drug ,administration1 the ,director of ,,nih shall include terms and conditions requiring that the price of such a drug or device for purposes of procurement by the ,federal ,government or if sold on the commercial market1 whether procured from1 or sold by1 the recipient of such ,federal award or another person-- 7#a7 is fair and reasonable1 taking into account-- 7,a7 the value of the drug and device to the public health1 including the impact of the price on access to the drug or device2 7,b7 the costs incurred by the ,federal ,government in research and development of the drug or device2 7,c7 the costs incurred by the recipient of the award in research and development of the drug or device1 and the costs of manufacturing such drug or device2 7,d7 whether the drug or device provided a significant improvement in health outcomes1 compared to other therapies available at the time of its approval or authorization2 7,e7 the cumulative expected global revenues generated by the drug or device2 and 7,f7 other factors1 as the ,secretary determines appropriate2 and 7#b7 does not exceed the lowest price charged for such drug or device1 among ,canada1 ,france1 ,germany1 ,italy1 ,japan1 and the ,united ,kingdom4 7e7 ,consultation ,in making a determination to award a grant1 contract1 or cooperative agreement for research projects relating to ,long ,,covid1 the ,director of ,,nih shall consult with the ,long ,,covid ,research ,advisory ,board4 ,members of the ,long ,,covid ,research ,advisory ,board shall provide a recommendation on any final funding decisions4 ,if the ,director of ,,nih makes a decision that is different than the recommendation1 the ,director of ,,nih shall provide a written justification for the decision within #e days4 #dii;,b-#c4 ,scientific ,review ,group 7a7 ,in general ,in order to ensure high quality1 rigorous scientific review of applications for grants1 contracts1 and cooperative agreements described in section #dii;,b-#b7;a71 consistent with section #dib1 the ,director of ,,nih shall establish a scientific review group on ,long ,,covid and other infection-associated chronic conditions1 and shall convene a group of leading scientific experts to serve on such group1 for terms of up to #e years4 7b7 ,duties ,the scientific research group shall conduct an initial review of applications for grants1 contracts1 and other cooperative agreements described in section #dii;,b-#b7;a71 and submit a funding recommendation to the ,director of ,,nih for final determination4 #dii;,b-#d4 ,long ,,covid ,research ,program ,advisory ,board 7a7 ,in general ,the ,director of ,,nih shall establish the ,long ,,covid ,research ,program ,advisory ,board 7referred to in this section as the ,advisory ,board74 7b7 ,membership 7#a7 ,in general ,the ,advisory ,board shall be comprised of #ah members1 including appointed members and nonvoting ex officio members1 as follows3 7,a7 ,the ,secretary shall conduct a nomination process that allows for public input on nominees4 ,the ,secretary shall appoint nominated individuals1 giving particular consideration to individuals from backgrounds that represent the diversity of the ,long ,,covid population1 with an emphasis on patients who face the highest disease burden4 ,individuals so appointed shall include the following3 7i7 #aj members who are scientists1 physicians1 and other health care professionals1 who are not officers or employees of the ,federal ,government1 and who have primary expertise in ,long ,,covid and other infection-associated chronic conditions1 with consideration given to such individuals with expertise in pediatric populations4 7ii7 #e members who live with ,long ,,covid4 7iii7 #a member who is a caregiver to an individual with ,long ,,covid4 7iv7 #b members who are employed by the ,national ,institutes of ,health and have expertise in ,long ,,covid research4 7,b7 ,the following shall be ex officio members of the ,advisory ,board3 7i7 ,a representative of the ,long ,,covid ,research ,program established under section #dii4 7ii7 ,a representative of the ,national ,institutes of ,health4 7iii7 ,a representative of the ,national ,institutes of ,neurological ,disorders and ,stroke4 7iv7 ,a representative of the ,national ,heart1 ,lung1 and ,blood ,institute4 7v7 ,a representative of the ,national ,institute of ,allergy and ,infectious ,diseases4 7vi7 ,a representative of the ,office of the ,assistant ,secretary for ,health4 7vii7 ,a representative of the ,centers for ,disease ,control and ,prevention4 7viii7 ,a representative of the ,administration for ,community ,living4 7ix7 ,a representative of the ,agency for ,healthcare ,research and ,quality4 7x7 ,representatives of any other agency or office of the ,department of ,health and ,human ,services that the ,secretary determines appropriate for the ,advisory ,board to carry out its function4 7#b7 ,engagement with organizations ,in appointing individuals to the ,advisory ,board1 the ,secretary shall engage with leading scientific experts on ,long ,,covid and independent1 patient-led organizations of advocacy groups representing ,long ,,covid patients4 7c7 ,compensation ,ex officio members of the ,advisory ,board who are officers or employees of the ,federal ,government shall not receive any compensation for service on the ,advisory ,board4 ,non-,federal members of the ,advisory ,board may receive1 for each day 7including travel time7 they are engaged in the performance of the functions of the advisory committee1 compensation at rates not to exceed the daily equivalent to the annual rate of basic pay for level ,,iii of the ,executive ,schedule under section #ecad of title #e1 ,united ,states ,code4 7d7 ,terms ,the term of office of an appointed member of the ,advisory ,board is #e years4 ,any member appointed to fill a vacancy for an unexpired term shall be appointed for the remainder of such term4 ,a member may serve after the expiration of the member's term until a successor has taken office4 ,if a vacancy occurs in the ,advisory ,board1 the ,secretary shall make an appointment to fill the vacancy not later than #fj days from the date the vacancy occurred4 7e7 ,chair ,the members of the ,advisory ,board shall select a chair from among the appointed members4 ,the term of the ,office of ,chair shall be #b years4 7f7 ,meetings 7#a7 ,in general ,the ,advisory ,board shall meet at the call of the chairman or upon request of the ,director of the ,program established under section #dii;,b1 but not less often than monthly in the first year after establishment1 then not less often than #f times a year for each subsequent year4 ,the meetings of the ,advisory ,board may be held virtually4 7#b7 ,purpose ,of the meetings held1 one or more shall be held to address research priorities of the ,national ,institutes of ,health relating to ,long ,,covid4 7#c7 ,publication of summary ,for each meeting held1 the ,director of ,,nih shall post on the website of the ,national ,institutes of ,health a summary of the proceedings4 7g7 ,duties ,the ,advisory ,board shall1 subject to the direction and supervision of the ,director of ,,nih-- 7#a7 review1 approve1 and evaluate the implementation of the research plan issued under section #dii;,b-#a1 and advise in updating the plan2 7#b7 provide guidance to the ,director of the ,program established under section #dii;,b with respect to appropriate research activities to be undertaken regarding the clinical treatment of ,long ,,covid1 which may include-- 7,a7 research on interventions for preventing1 treating1 and understanding the mechanisms of ,long ,,covid2 7,b7 research on the effectiveness of treating ,long ,,covid with drugs that are not yet approved by the ,food and ,drug ,administration for the treatment of ,long ,,covid2 7,c7 reviewing ongoing publicly- and privately-supported research on treatments for ,long ,,covid2 7,d7 issue and make available to health care professionals and the public reports describing and evaluating research described in subparagraphs 7,a71 7,b71 and 7,c72 and 7,e7 convene accessible meetings for the purpose of determining the recommendations which may inform development of clinical guidelines by health care provider organizations2 and 7#c7 engage in other necessary activities to contribute to the ,national ,institutes of ,health's overall research priorities related to ,long ,,covid1 and ensure accountability1 transparency1 and communication of results of the ,program established under section #dii;,b4 4 #dii;,b-#e4 ,data system and clearinghouse on research information 7a7 ,data system 7#a7 ,in general ,the ,director of the ,national ,institutes of ,health1 in consultation with the ,director of the ,program established under section #dii;,b and the ,director of the ,national ,library of ,medicine shall establish1 maintain1 and operate a data system for the collection1 storage1 analysis1 retrieval1 and timely dissemination of primary data regarding research on ,long ,,covid that is conducted or supported by the ,program4 ,information from the data system shall be available through information systems available to health care professionals and providers1 researchers1 and members of the public4 7#b7 ,registry 7,a7 ,in general ,the data system established under paragraph 7#a7 shall include a registry of clinical trials of experimental treatments that have been developed for research on ,long ,,covid4 ,such registry shall include information on patient eligibility criteria1 including the definition of ,long ,,covid1 and1 as applicable1 demographic information1 including sex1 age1 disability status1 ethnicity1 and race1 and the location of the trial site or sites4 7,b7 ,submission of information ,principal investigators of trials described in subparagraph 7,a7 shall provide such information to the registry not later than #cj days after public announcement of the clinical trial4 ,once a trial has been completed1 the principal investigator shall provide the registry with information pertaining to the results1 including potential toxicities or adverse effects associated with the experimental treatment or treatments evaluated4 7,c7 ,public availability ,the registry described in this paragraph shall be made available to researchers and the general public1 in a machine-readable format4 7b7 ,clearinghouse ,the ,director of ,,nih1 in consultation with the ,director of the ,program and with the ,national ,library of ,medicine1 shall establish1 maintain1 and operate a program to provide information on research and prevention activities of the national research institutes that relate to research on ,long ,,covid4 #dii;,b-#f4 ,appropriations ,for purposes of carrying out this part1 there are appropriated1 out of amounts in the ,treasury not otherwise appropriated1 #a1jjj1jjj1jjj for each of fiscal years #bjbe through #bjcd1 to remain available until expended4 4 ,,ii ,public ,health ,research1 ,surveillance and ,related ,activities #bja4 ,long ,,covid programs ,title ,,iii of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bda et seq47 is amended by adding at the end the following3 ,x ,long ,,covid activities #cii,,pp4 ,public ,health ,surveillance of ,long ,,covid and infection-associated chronic conditions 7a7 ,in general ,the ,secretary1 acting through the ,director of the ,centers for ,disease ,control and ,prevention1 shall establish or continue1 as applicable1 surveillance activities to better understand the burden and severity of ,long ,,covid and related infection-associated chronic conditions1 with specific consideration given to vulnerable populations1 such as children4 ,in carrying out this section1 the ,secretary shall-- 7#a7 collect data on the incidence1 prevalence1 and severity of ,long ,,covid and related infection-associated chronic conditions2 7#b7 monitor for ,long ,,covid and ,long ,,covid-like conditions1 as appropriate1 to enable early intervention and identification of factors associated with severity of symptoms2 7#c7 compile1 and make publicly available1 in accessible formats1 ,long ,,covid data collected under paragraph 7#a72 7#d7 develop and disseminate best practices for conducting surveillance for ,state1 local1 and ,tribal public health officials1 and other relevant public health stakeholders2 7#e7 provide technical assistance to international organizations1 as applicable1 regarding the monitoring of ,long ,,covid2 and 7#f7 conduct additional surveillance activities1 as the ,secretary determines appropriate1 to better understand the burden and severity of ,long ,,covid4 7b7 ,authorization of appropriations ,for purposes of carrying out this section1 there are authorized to be appropriated #cb1jjj1jjj for each of fiscal years #bjbe through #bjcd4 #cii,,pp-#a4 ,public health programming 7a7 ,in general ,the ,secretary1 acting through the ,director of the ,centers for ,disease ,control and ,prevention1 shall make grants to ,state1 local1 and ,tribal health departments for the purpose of carrying out activities related to ,long ,,covid4 7b7 ,use of funds ,a ,state1 local1 or ,tribal health department that receives a grant under subsection 7a7 may use funds received through such grant to-- 7#a7 provide training on the identification of ,long ,,covid to clinicians1 public health experts1 and other relevant health care professionals2 7#b7 link individuals with ,long ,,covid to care1 as appropriate and applicable2 7#c7 support the development and dissemination of public information and educational materials on ,long ,,covid1 including materials to address misinformation and disinformation2 7#d7 support laboratory capacity for screening and diagnosis of ,long ,,covid and associated symptoms2 and 7#e7 build1 maintain1 and sustain jurisdiction-level infrastructure related to preparedness for post-infectious syndromes4 7c7 ,authorization of appropriations ,for purposes of carrying out this section1 there are authorized to be appropriated #de1jjj1jjj for each of fiscal years #bjbe through #bjcd4 #cii,,pp-#b4 ,national public education campaign on ,long ,,covid 7a7 ,in general ,the ,secretary1 acting through the ,director of the ,centers for ,disease ,control and ,prevention1 and in collaboration with national1 ,state1 local1 and ,tribal public health partners1 shall develop a public education campaign for patients1 families1 and caregivers to educate and increase awareness about ,long ,,covid in children and adults4 ,such campaign shall include information on-- 7#a7 the signs and symptoms of ,long ,,covid2 7#b7 how to prevent and seek treatment for ,long ,,covid2 7#c7 self-management tools and support services2 and 7#d7 other topics1 as the ,secretary determines appropriate4 7b7 ,consultation ,in developing materials for the campaign1 the ,secretary shall consult with independent1 patient-led organizations or advocacy groups representing ,long ,,covid patients and their families and other relevant stakeholders4 7c7 ,accessibility ,the public education campaign under this section shall be made available in multiple languages1 including ,american ,sign ,language4 7d7 ,authorization of appropriations ,for purposes of carrying out this section1 there are authorized to be appropriated #ba1ejj1jjj for each of fiscal years #bjbe through #bjbi4 #cii,,pp-#c4 ,provider education 7a7 ,in general ,the ,secretary shall-- 7#a7 develop and make publicly available best practices for coordinated1 multidisciplinary care for individuals with ,long ,,covid2 7#b7 develop1 update1 as appropriate1 and make publicly available clinical guidance and provider education materials1 including for providers working with pediatric populations2 and 7#c7 facilitate provider education on ,long ,,covid signs1 symptoms1 maintenance1 and treatment1 including through technology-enabled collaborative learning4 7b7 ,authorization of appropriations ,for the purpose of carrying out this section1 there are authorized to be appropriated #c1jjj1jjj for each of fiscal years #bjbe through #bjcd4 4 #bjb4 ,rehabilitation ,research and ,training ,center on ,long ,,covid among people with disabilities 7a7 ,in general ,section #bdj7;b77#b77;,c7 of the ,rehabilitation ,act of #aigc 7#bi ,u4,s4,c4 #gfd7;b77#b77;,c77 is amended-- 7#a7 in clause 7v71 by striking 2 and and inserting a semicolon2 7#b7 in clause 7vi71 by striking the period and inserting 2 and2 and 7#c7 by adding at the end the following3 7vii7 applied research regarding evidence-based treatments1 services1 and supports for individuals with disabilities with ,long ,,covid or other infection-associated chronic conditions4 4 7b7 ,authorization of appropriations ,to carry out the amendment made by subsection 7b71 there are authorized to be appropriated to the ,director of the ,national ,institute on ,disability1 ,independent ,living1 and ,rehabilitation ,research1 #aj1jjj1jjj for the period of fiscal years #bjbe through #bjbi4 #bjc4 ,clinical outcomes assessments 7a7 ,in general ,the ,secretary of ,health and ,human ,services1 acting through the ,commissioner of ,food and ,drugs1 shall establish or continue the development and validation of clinical outcomes assessments to support regulatory decision making for drugs1 including biological products1 and devices used to treat ,long ,,covid4 7b7 ,authorization of appropriations ,for purposes of carrying out this section1 there are authorized to be appropriated #i1jjj1jjj for each of fiscal years #bjbe through #bjcd4 #bjd4 ,electronic reporting form 7a7 ,in general ,the ,secretary of ,health and ,human ,services1 acting through the ,commissioner of ,food and ,drugs1 shall establish or continue the development1 refinement1 and maintenance of a ,long ,,covid electronic reporting form for patients to identify current treatments and treatments under development for ,long ,,covid4 7b7 ,authorization of appropriations ,for purposes of carrying out this section1 there are authorized to be appropriated #af1fjj1jjj for each of fiscal years #bjbe through #bjcd4 #bje4 ,long ,,covid care network 7a7 ,in general ,the ,secretary of ,health and ,human ,services1 acting through the ,director of the ,agency for ,healthcare ,research and ,quality1 shall develop1 or continue to support1 multidisciplinary ,long ,,covid clinics to provide access to comprehensive1 coordinated care for individuals with ,long ,,covid1 particularly underserved populations that are disproportionately impacted by the effects of ,long ,,covid4 7b7 ,authorizations of appropriations ,for purposes of carrying out this section1 there are authorized to be appropriated #aj1jjj1jjj for each of fiscal years #bjbe through #bjcd4 #bjf4 ,research on long covid best practices 7a7 ,in general ,the ,secretary of ,health and ,human ,services1 in coordination with the ,director of the ,agency for ,healthcare ,research and ,quality1 shall develop1 test1 synthesize1 and disseminate best practices and decision support tools related to the clinical care organization1 delivery1 and integration of clinical and social services for ,long ,,covid and other infection-associated chronic conditions4 7b7 ,authorization of appropriations ,for the purposes of carrying out this section1 there are authorized to be appropriated #aj1jjj1jjj for each of fiscal years #bjbe through #bjcd4